n.a. (PCYC)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

These Stocks Get Benefit of the Doubt

Market backtracks on skepticism over biotechs.

What Is Wrong With You People?

These companies are doing great -- take some profits!

Jim Cramer on Biotech Stocks the Market Always Seems to Undervalue

Jim Cramer on Biotech Stocks the Market Always Seems to Undervalue

It shouldn't be possible, but it never seems too late to get in.

Jim Cramer's 'Mad Money' Recap: This Is One Stupid Market

Jim Cramer's 'Mad Money' Recap: This Is One Stupid Market

It's creating investment opportunities that just shouldn't exist, Cramer says.

Market Rewards Biotech Latecomers

It shouldn't be possible, but it never seems too late to get in.

Jim Cramer's Trust Sells Out of AbbVie: What Wall Street's Saying

Jim Cramer's Trust Sells Out of AbbVie: What Wall Street's Saying

Jim Cramer's charitable trust closed out its position in AbbVie on Tuesday, citing concerns for its 'expensive' acquisition plans for Pharmacylics.

PHARMACYCLICS INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Sale To AbbVie

PHARMACYCLICS INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Sale To AbbVie

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Pharmacyclics...

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Pharmacyclics Inc. Of Commencement Of Class Action Investigation Concerning The Fairness Of The Sale Of The Company To AbbVie

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Pharmacyclics Inc. Of Commencement Of Class Action Investigation Concerning The Fairness Of The Sale Of The Company To AbbVie

The following statement is being issued by Levi & Korsinsky, LLP: TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED COMMON STOCK OF PHARMACYCLICS INC.

Value in Good Management; Biotechs Are Feeling Better: Jim Cramer's Best Blogs

Value in Good Management; Biotechs Are Feeling Better: Jim Cramer's Best Blogs

Catch up on Jim Cramer's thinking over the last week about the sheer power of execution and the much-needed bounceback in biotech.

Jim Cramer's 'Mad Money' Recap: Why Aren't Well-Run Companies Getting Respect?

Jim Cramer's 'Mad Money' Recap: Why Aren't Well-Run Companies Getting Respect?

Cramer says what seems overvalued on paper today might surprise you and be in a whole new category tomorrow.

Stocks Notch Small Gains Ahead of February Jobs Report

Stocks Notch Small Gains Ahead of February Jobs Report

Stocks manage to close with gains on Thursday, but just barely ahead of the February jobs report on Friday

That's Just What's Supposed to Happen

Stocks that stabilized yesterday were terrific today.

Stocks' Gains Are Limited in Lead-Up to February Jobs Report

Stocks' Gains Are Limited in Lead-Up to February Jobs Report

Stocks regain positive momentum by mid-afternoon. Weaker-than-expected domestic data and the materials sector kept gains limited.

Value in Good Management

Kroger is a good example of execution.

Deutsche Says AbbVie Deal Positive, While Piper Calls Price Too High

Deutsche Says AbbVie Deal Positive, While Piper Calls Price Too High

AbbVie agreed to buy Pharmacyclics for $261.25 per share, or $21B, the companies announced late last night.

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Pharmacyclics Inc. Of Commencement Of Class Action Investigation Concerning The Fairness Of The Sale Of The Company To AbbVie -- PCYC

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Pharmacyclics Inc. Of Commencement Of Class Action Investigation Concerning The Fairness Of The Sale Of The Company To AbbVie -- PCYC

The following statement is being issued by Levi & Korsinsky, LLP: TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED COMMON STOCK OF PHARMACYCLICS INC.

Pharmacyclics (PCYC) Stock Spikes Today Following $21 Billion AbbVie Merger Deal

Pharmacyclics (PCYC) Stock Spikes Today Following $21 Billion AbbVie Merger Deal

Pharmacyclics (PCYC) shares are up double digits after the company announced that it was purchased by AbbVie (ABBV) for $21 billion.

Stocks Grind Higher on ECB's QE While Costco Boosts S&P 500

Stocks Grind Higher on ECB's QE While Costco Boosts S&P 500

Stocks rise Thursday after the European Central Bank announced the start date of its quantitative-easing program.

AbbVie to Acquire Pharmacyclics: What Wall Street's Saying

AbbVie to Acquire Pharmacyclics: What Wall Street's Saying

Shares of Pharmacyclics surge after AbbVie announces plans to acquire the maker of leukemia drugs for $21 billion.

Stock Futures Are Pointing Higher as ECB Lifts Growth Forecast

Stock Futures Are Pointing Higher as ECB Lifts Growth Forecast

Stock futures set up for a bounce at the open, hoping to reverse some of the losses sustained over the past two sessions.

Credit Suisse: 8 Biotech and Health Care Stocks Add to Your Portfolio Right Now

Credit Suisse: 8 Biotech and Health Care Stocks Add to Your Portfolio Right Now

Biotechnology and health care in general are some of the hottest areas for investment these days.

March 5 Premarket Briefing: 10 Things You Should Know

March 5 Premarket Briefing: 10 Things You Should Know

U.S. stock futures are looking positive on a big drugmaker deal and after two down days in the market.

Trade-Ideas: Pharmacyclics (PCYC) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas: Pharmacyclics (PCYC) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas LLC identified Pharmacyclics (PCYC) as a pre-market mover with heavy volume candidate

AbbVie Spending Historic Amount of Cash to Buy Half of a Cancer Drug

AbbVie Spending Historic Amount of Cash to Buy Half of a Cancer Drug

The $21 billion price tag for Pharmacylics only earns AbbVie rights to 50% of the blood cancer drug Imbruvica.

China Cuts Growth Target

And four other things you need to know now.

Jim Cramer's 'Mad Money' Recap: The Market Is a Battlefield

Jim Cramer's 'Mad Money' Recap: The Market Is a Battlefield

Investors have to pay attention to see what's really worth buying.

The Biotechs Are Feeling Better

Sector could regain its leadership role.

Trade-Ideas: Pharmacyclics (PCYC) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Pharmacyclics (PCYC) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Pharmacyclics (PCYC) as a strong on high relative volume candidate